RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to Bcl-xL-expressing myeloma cells in vitro and in vivo

Jonathan B. Pollett, Yuan Xiao Zhu, Sonal Gandhi, Meena Bali, Esther Masih-Khan, Zhihua Li, Xiao Yan Wen, Alexander Keith Stewart

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The antiapoptotic protein bcl-xL is upregulated in a variety of solid tumors and in primary hematologic malignancies such as multiple myeloma. Activated caspase-3 cleaves proteins essential for cell survival, including bcl-xL. To explore the potential of caspase-3 as a cytotoxic and immunostimulatory molecule in the treatment of malignancy, an RU486-inducible caspase-3 retrovirus was constructed, validated, and used to transduce first 3T3 and subsequently murine myeloma B9BM1 cells (creating the cell line B9BM-C3). After induction, apoptotic cell death of 3T3 and B98M-C3 cells began by 4 h and was complete by 48 h postinduction, while nontransduced cells remained viable. Annexin V staining demonstrated 43, 76, and 98% apoptotic cell death at 12, 18, and 24 h postinduction. Activation of caspase-3 was evident in induced cells and cell death could be inhibited by the addition of a caspase-3-specific inhibitor. Overexpression of the myeloma-associated oncogene FGFR3, which upregulates bcl-xL, delayed but did not prevent caspase-3-mediated killing. B9BM-C3 cells formed tumors after subcutaneous injection in mice. Early treatment with RU486 eradicated tumors; however, rechallenge of treated mice failed to demonstrate evidence of immunoprotection. These results indicate that therapeutic attempts to induce caspase-3 in malignant cells may prove useful in the treatment of bcl-xL-expressing tumors.

Original languageEnglish (US)
Pages (from-to)230-237
Number of pages8
JournalMolecular Therapy
Volume8
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Retroviridae
Caspase 3
Cell Death
Neoplasms
Annexin A5
Hematologic Neoplasms
Subcutaneous Injections
Therapeutics
In Vitro Techniques
Multiple Myeloma
Oncogenes
Cell Survival
Proteins
Up-Regulation
Staining and Labeling
Cell Line

Keywords

  • Apoptosis
  • bcl-x
  • Caspase-3
  • Myeloma
  • Retrovirus
  • RU486

ASJC Scopus subject areas

  • Molecular Biology

Cite this

RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to Bcl-xL-expressing myeloma cells in vitro and in vivo. / Pollett, Jonathan B.; Zhu, Yuan Xiao; Gandhi, Sonal; Bali, Meena; Masih-Khan, Esther; Li, Zhihua; Wen, Xiao Yan; Stewart, Alexander Keith.

In: Molecular Therapy, Vol. 8, No. 2, 01.08.2003, p. 230-237.

Research output: Contribution to journalArticle

Pollett, Jonathan B. ; Zhu, Yuan Xiao ; Gandhi, Sonal ; Bali, Meena ; Masih-Khan, Esther ; Li, Zhihua ; Wen, Xiao Yan ; Stewart, Alexander Keith. / RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to Bcl-xL-expressing myeloma cells in vitro and in vivo. In: Molecular Therapy. 2003 ; Vol. 8, No. 2. pp. 230-237.
@article{a227a84b9b6d439baefb59aed7626fe0,
title = "RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to Bcl-xL-expressing myeloma cells in vitro and in vivo",
abstract = "The antiapoptotic protein bcl-xL is upregulated in a variety of solid tumors and in primary hematologic malignancies such as multiple myeloma. Activated caspase-3 cleaves proteins essential for cell survival, including bcl-xL. To explore the potential of caspase-3 as a cytotoxic and immunostimulatory molecule in the treatment of malignancy, an RU486-inducible caspase-3 retrovirus was constructed, validated, and used to transduce first 3T3 and subsequently murine myeloma B9BM1 cells (creating the cell line B9BM-C3). After induction, apoptotic cell death of 3T3 and B98M-C3 cells began by 4 h and was complete by 48 h postinduction, while nontransduced cells remained viable. Annexin V staining demonstrated 43, 76, and 98{\%} apoptotic cell death at 12, 18, and 24 h postinduction. Activation of caspase-3 was evident in induced cells and cell death could be inhibited by the addition of a caspase-3-specific inhibitor. Overexpression of the myeloma-associated oncogene FGFR3, which upregulates bcl-xL, delayed but did not prevent caspase-3-mediated killing. B9BM-C3 cells formed tumors after subcutaneous injection in mice. Early treatment with RU486 eradicated tumors; however, rechallenge of treated mice failed to demonstrate evidence of immunoprotection. These results indicate that therapeutic attempts to induce caspase-3 in malignant cells may prove useful in the treatment of bcl-xL-expressing tumors.",
keywords = "Apoptosis, bcl-x, Caspase-3, Myeloma, Retrovirus, RU486",
author = "Pollett, {Jonathan B.} and Zhu, {Yuan Xiao} and Sonal Gandhi and Meena Bali and Esther Masih-Khan and Zhihua Li and Wen, {Xiao Yan} and Stewart, {Alexander Keith}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1525-0016(03)00146-1",
language = "English (US)",
volume = "8",
pages = "230--237",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to Bcl-xL-expressing myeloma cells in vitro and in vivo

AU - Pollett, Jonathan B.

AU - Zhu, Yuan Xiao

AU - Gandhi, Sonal

AU - Bali, Meena

AU - Masih-Khan, Esther

AU - Li, Zhihua

AU - Wen, Xiao Yan

AU - Stewart, Alexander Keith

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The antiapoptotic protein bcl-xL is upregulated in a variety of solid tumors and in primary hematologic malignancies such as multiple myeloma. Activated caspase-3 cleaves proteins essential for cell survival, including bcl-xL. To explore the potential of caspase-3 as a cytotoxic and immunostimulatory molecule in the treatment of malignancy, an RU486-inducible caspase-3 retrovirus was constructed, validated, and used to transduce first 3T3 and subsequently murine myeloma B9BM1 cells (creating the cell line B9BM-C3). After induction, apoptotic cell death of 3T3 and B98M-C3 cells began by 4 h and was complete by 48 h postinduction, while nontransduced cells remained viable. Annexin V staining demonstrated 43, 76, and 98% apoptotic cell death at 12, 18, and 24 h postinduction. Activation of caspase-3 was evident in induced cells and cell death could be inhibited by the addition of a caspase-3-specific inhibitor. Overexpression of the myeloma-associated oncogene FGFR3, which upregulates bcl-xL, delayed but did not prevent caspase-3-mediated killing. B9BM-C3 cells formed tumors after subcutaneous injection in mice. Early treatment with RU486 eradicated tumors; however, rechallenge of treated mice failed to demonstrate evidence of immunoprotection. These results indicate that therapeutic attempts to induce caspase-3 in malignant cells may prove useful in the treatment of bcl-xL-expressing tumors.

AB - The antiapoptotic protein bcl-xL is upregulated in a variety of solid tumors and in primary hematologic malignancies such as multiple myeloma. Activated caspase-3 cleaves proteins essential for cell survival, including bcl-xL. To explore the potential of caspase-3 as a cytotoxic and immunostimulatory molecule in the treatment of malignancy, an RU486-inducible caspase-3 retrovirus was constructed, validated, and used to transduce first 3T3 and subsequently murine myeloma B9BM1 cells (creating the cell line B9BM-C3). After induction, apoptotic cell death of 3T3 and B98M-C3 cells began by 4 h and was complete by 48 h postinduction, while nontransduced cells remained viable. Annexin V staining demonstrated 43, 76, and 98% apoptotic cell death at 12, 18, and 24 h postinduction. Activation of caspase-3 was evident in induced cells and cell death could be inhibited by the addition of a caspase-3-specific inhibitor. Overexpression of the myeloma-associated oncogene FGFR3, which upregulates bcl-xL, delayed but did not prevent caspase-3-mediated killing. B9BM-C3 cells formed tumors after subcutaneous injection in mice. Early treatment with RU486 eradicated tumors; however, rechallenge of treated mice failed to demonstrate evidence of immunoprotection. These results indicate that therapeutic attempts to induce caspase-3 in malignant cells may prove useful in the treatment of bcl-xL-expressing tumors.

KW - Apoptosis

KW - bcl-x

KW - Caspase-3

KW - Myeloma

KW - Retrovirus

KW - RU486

UR - http://www.scopus.com/inward/record.url?scp=0041353611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041353611&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(03)00146-1

DO - 10.1016/S1525-0016(03)00146-1

M3 - Article

C2 - 12907145

AN - SCOPUS:0041353611

VL - 8

SP - 230

EP - 237

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -